Attorney General Aaron M. Frey announced a settlement agreement with Sanofi-Aventis U.S. LLC after scrutiny over the ...

More than three years after approving two biosimilars referencing Sanofi’s long-acting insulin Lantus, the FDA has signed off on a rapid-acting insulin biosimilar for the first time. The agency ...

Under the settlement, Mainers who are uninsured or have commercial health insurance will be eligible to purchase monthly ...

In 2023, Sanofi jumped the bandwagon with the other two insulin U.S. giants to lower the price of its best-selling insulin product, Lantus (insulin glargine), by 78%. Sanofi said it would cap a ...

Sanofi's rivals in the insulin field are nipping at its heels – Lantus sales dipped 5 per cent in the first half of 2015, and analysts don't expect Toujeo to make up for its decline.

Who Are the Key Players in the Lantus Market? The Lantus market features several major pharmaceutical companies, with Sanofi S.A. being a leading player. Industry giants like Sanofi contribute to ...

On average, insulin glargine biosimilars achieve a 26% market share after 5 years on the market. 3 Sanofi's dual pricing strategy may have slowed the market uptake of insulin biosimilars ...